Navigation Links
Signalife Provides Corporate Update

Friday, August 31, 9:15 am ET

LOS ANGELES, Aug. 31 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN), Lowell T. Harmison, President and acting Chief Executive, has release the following corporate update since his matriculation into the Presidency last month:

1. Dr. Harmison has already "cleaned house" and has eliminated several

positions that were producing no revenue whatsoever and no hope of any

positive results for the Company, in his view. That was done

immediately by Dr. Harmison and was done by the Dr. personally. "We

are now operating within five separate departments: Sales, R&D,

Operations, FDA, Regulatory. These positions are now compartmentalized

and operating efficiently under my direct supervision."

2. As promised, and as announced, Dr. Harmison has participated in

obtaining a $102 million financing vehicle for the Company. Dr.

Harmison calls this an "extremely valuable" facility, because it

enables the company to choose the market conditions - and stock price -

at which it shall exchange its stock for capital." Dr. Harmison

continues: "We are thankful to the AMEX for so efficiently and in good

faith evaluating and approving our financing transaction. The market

appears to be getting the message that - when my sales initiatives bear

fruit in the upcoming near term - the obtaining of $100 million at the

market price is a testament to our technology - referred to as a

"modern medical miracle" by NBC. Any other result would have been

unfair to our shareholders, and I promised that I would create a new

era for our shareholders - one with revenues, earnings, profits, growth

and corporate accolades."

3. According to Dr. Harmison, "our sales funnel utilizing marquee

hospitals known to the Company and its Board" is proceeding ahead of

schedule. These are some of the prestigious institutions in the

country and allow the marvelous Fidelity 100 to be utilized in areas

where lives and outcomes can be changed for the better. I anticipate

our market penetration strategy over the next five quarters will

proceed more quickly than I had conservatively anticipated at the

beginning of my tenure."

4. The technology division is also moving on its holter devices as well as

its intra-cardiac monitor - and other devices - with extraordinary

acuity and speed. The division - possibly the core of the Company -

"only gets more efficient as the secrets of the patented technologies

become more known and understood in the quality of the signal from

heart patients of all ages."

"In short, I have achieved more than I anticipated in several short weeks, and the momentum toward device approvals, ventures, sales and earnings are at the center of that gaining momentum. I am still planning on a near-term conference call with the marketplace, but I wish to complete certain touchstone events before having that call. I am always available for shareholder calls and can be reached through our corporate offices," added Dr. Harmison.

About Signalife:

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements:

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.

SOURCE Signalife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures
2. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
3. State provides $200K for Necedah ethanol plant
4. Madison firm provides $200K in capital to tech companies
5. Mirus provides low-cost way to modify genes
6. MDC provides venture funding for tech companies
7. IT Fusion SOS provides outsourced IT aid to small businesses
8. BIO provides forum for Wisconsin to showcase strengths
9. Imago provides atomic probe to Australian lab
10. Online Kiosks provides a new way to send a message
11. Small Tree provides Apple drivers for Intels new 10-gigabit Ethernet cards
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
Breaking Biology Technology:
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
(Date:10/26/2015)... , October 26, 2015 ... --> adds Biometrics Market ... 2021 as well as Emerging Biometrics ... reports to its collection of IT ... . --> ...
(Date:10/23/2015)... 2015 Research and Markets ( ) ... Recognition Biometrics Market 2015-2019" report to their offering. ... The global voice recognition biometrics market to grow at ... --> --> The report, Global ... on an in-depth market analysis with inputs from industry ...
Breaking Biology News(10 mins):